| The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era. | |
| | |
MedLine Citation:
|
PMID: 15803434 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Many studies have investigated the process of left ventricular (LV) dilatation and the effects of angiotensin-converting enzyme (ACE) inhibitors after myocardial infarction (MI). It has been generally accepted that progression of LV dilatation is a major predictor of heart failure and death after MI. Also, attenuation of LV dilatation is thought to be one of the main mechanisms by which ACE inhibitors (ACE-Is) produce their beneficial effects. However, evidence for this hypothesis came from studies that were performed before thrombolytic therapy and primary percutaneous coronary intervention (PCI) were routinely used after acute MI. Nowadays, reperfusion is obtained much more frequently and LV dilatation after MI has become less prevalent. Nevertheless, ACE-Is proved effective in reducing cardiac morbidity and mortality. Therefore, mechanisms other than attenuation of LV dilatation, such as anti-atherosclerotic effects or plaque stabilisation, may explain the long-term beneficial effects of ACE-Is after MI. In the present overview, we evaluate the role of LV dilatation and the effects of ACE-Is after MI in the thrombolytic/primary PCI era and provide recommendations on ACE-I use in clinical practice. |
| | |
Authors:
|
Pieter J de Kam; Adriaan A Voors; Francesco Fici; Dirk J van Veldhuisen; Wiek H van Gilst |
Related Documents
:
|
11880804 - The relationship of heart rate reserve to vo2 reserve in patients with heart disease. 16226174 - C-reactive protein increase in unstable coronary disease cause or effect? 17317364 - Prognostic value of location and type of myocardial infarction in the setting of advanc... 20837904 - Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodel... 22819444 - Bidirectional ventricular tachycardia secondary to subacute myocarditis. 16845254 - Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coro... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of the renin-angiotensin-aldosterone system : JRAAS Volume: 5 ISSN: 1470-3203 ISO Abbreviation: J Renin Angiotensin Aldosterone Syst Publication Date: 2004 Dec |
Date Detail:
|
Created Date: 2005-04-01 Completed Date: 2005-06-20 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 100971636 Medline TA: J Renin Angiotensin Aldosterone Syst Country: England |
Other Details:
|
Languages: eng Pagination: 161-8 Citation Subset: IM |
Affiliation:
|
Organon, Oss, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary* Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Fibrinolytic Agents / therapeutic use* Humans Myocardial Infarction / drug therapy, therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Fibrinolytic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence of diabetic retinopathy in the Regional Comunity of Extremadura. 1997-2001 (Extremadura P...
Next Document: Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells.